Kornimate/medical-research-clean huggingface dataset:
low level laser light therapy and chronic neck and shoulder pain

Conditions: Shoulder Pain; Neck Pain; Musculoskeletal Pain; Musculoskeletal Strain; Musculoskeletal Sprain

Summary: the purpose of this study was to determine whether the application of low level laser light therapy to the neck and shoulder region is effective in reducing chronic neck and shoulder pain of musculoskeletal origin.

chronic neck and shoulder pain arising from osteoarthritis, chronic muscle spasms or thoracic or cervical spine sprain strain can be seriously debilitating. currently available treatment options such as pain relief medication, ice pack, massage, physical therapy and chiropractic are typically of limited effectiveness. more permanent options such as surgery are invasive with long recovery periods and side-effects and complications of their own. low level laser light therapy, with its proven anti-inflammatory ability, offers a simple non-invasive option for the reduction of chronic neck and shoulder pain.

Eligibility criteria:
inclusion criteria: * location of pain is on the right and/or left side of the neck and/or shoulder and/or the back of the neck. * etiology of pain is osteoarthritis/degenerative joint disorder (djd); chronic muscle spasms or cervical and thoracic spine sprain strain, determined according to subject medical history, medication use history, previous records review, physical examination of the cervical spine and shoulder. * stage of injury is chronic, having prevailed for longer than 30 days. * degree of pain self-rating of 50 or greater on the 0-100 visual analog scale (vas). * 18-65 years. exclusion criteria: * stage of injury is acute, having prevailed for less than 30 days. * known herniated disc injury. * any other disease or condition that may cause or contribute to the chronic pain condition. * presence of infection or open wound at the treatment areas. * use of steroids or narcotics. * use of over-the-counter (otc) medication for the relief of pain within the 24-hour period prior to participating in the treatment phase of the study, or prescription medication for the relief of pain within the 48-hour period prior to participating in the treatment phase of the study. * pregnant or lactating.

Keywords: chronic pain neck shoulder musculoskeletal origin
a comparative study of azithromycin and s-p as prophylaxis in pregnant hiv+ patients

Conditions: Malaria; Pregnant; HIV

Summary: randomized controlled single blind prospective comparative study

this study is intended to be a randomized controlled single blind prospective comparative study conducted to compare the efficacy of three monthly doses of sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria with azithromycin in hiv positive pregnant women

Eligibility criteria:
inclusion criteria: * pregnant hiv positive patients, * gestational age 16 weeks and above, * no history of azithromycin or sulphadoxine-pyrimethamine use four weeks prior to recruitment exclusion criteria: * anaemia packed cell volume less than 30%, * pre-existing medical conditions- diabetes mellitus, * hypertension, * allergy to sulphadoxine-pyrimethamine or azithromycin

Keywords: ipt malaria pregnant hiv positive
reduction of spontaneous prematurity by antibiotic treatment (josamycin)

Conditions: Prematurity

Summary: the purpose of this study is to test the effectiveness of an antibiotic treatment (josamycin) in the case of positive pcr for ureaplasma spp. and/or mycoplasma hominis in the second quarter on the risk of premature birth.

infection would be the cause of 40 % of spontaneous premature deliveries. the physiopathological hypothesis accepted is a premature ascent of present bacteria in the low genital ways towards the decidual, the foetal membranes then the amniotic liquid. these bacteria are responsible for an inflammatory reaction to the interface feto-maternal characterized by the production of proinflammatory cytokines and pro-contractants agents (prostaglandins, oxytocin) by the decidual and the membranes. these mediators cause uterine contractions, a maturation of the uterine collar, a rupture of the membranes then a premature birth. several recent publications show on the one hand that mycoplasma hominis and ureaplasma spp. are the bacteria most frequently found in the amniotic liquid in the second quarter of the pregnancy and that a positive pcr for these bacteria is associated with a premature birth. a probable assumption would be that mycoplasma hominis or ureaplasma spp. cause a premature birth by infecting the fetal membranes and the decidual, then activating the immune system and the pro-inflammatory production of cytokines. these bacteria are sensitive to antibiotic treatment. nevertheless, no randomized controlled trials have been carried out to determine wether an antibiotic treatment would decrease spontaneous prematurity in the case of positive pcr in the amniotic liquid.

Eligibility criteria:
inclusion criteria: * patient older ≥ 18 years * french speaking * women who have an amniocentesis between 15 and 20 weeks of amenorrhoea for an antenatal diagnosis * affiliated to social security or an equivalent system * karyotype analysis and ultrasound morphological normal (apart from minor signs of trisomy 21) * clear amniotic fluid (not contaminated by the mother's blood) * gestational age is between 15 wa(day+0) and 20 wa(day+6) * patient have not allergy to macrolides * do not have cure underway by macrolide * patient followed during her pregnancy in an investigator site * informed consent and signed exclusion criteria: * no speaking french * having an allergy to macrolides * having a multiple pregnancy * morphological anomaly * patient no consented * lactose intolerance * not agreed to participate

Keywords: prematurity ureaplasma spp mycoplasma hominis amniotic fluid josamycine
the effect of therapeutic play before dressing on anxiety and fear in children

Conditions: Anxiety; Fear

Summary: the goal of this experimental study is to determine the effect of therapeutic play method applied to hospitalized children aged 7-12 before the first surgical dressing attempt, on anxiety and fear. researcher will compare the study and control groups to see if therapeutic play has an effect on anxiety and fear.

g-power 3.1.9.4 package program was used for sample size calculation in the study. children will be assigned to the study and control groups using the www.randomizer.org program with a simple randomization method to ensure homogeneity between the study and control groups. before dressing, a warm-up play will be played for 10 minutes with the study group, followed by a 20-minute therapeutic game in which the dramatization method will be used. the children in the control group will be subjected to the routine dressing procedure. the data of the research will be collected using the child and parent information form, child anxiety scale-state scale and child fear scale. during the evaluation of the data, the sociodemographic characteristics of the groups participating in the study will be stated as numbers and percentages, and the normal distribution of the anxiety scale and fear scale scores before the play, after the play and after the dressing process in the intervention and control groups will be determined by looking at the skewness coefficients. the factorial anova test will be used for mixed measurements in order to examine the anxiety and fear changes of the children in the intervention and control groups before the play, after the play and after the dressing process. in addition, since this test does not measure the different changes between the groups, the anova test in repeated measurements will be used to compare the anxiety and fear scores of only the intervention group and only the control group before the play, after the play and after the dressing process. if the data do not have a normal distribution, the friedman test, which is a nonparametric test, will be used.

Eligibility criteria:
inclusion criteria: * children in the 7-12 age group * children who speak and understand turkish * children whose first dressing will be done in the service on the second day after the operation exclusion criteria: * children with hearing, vision and speech problems in themselves or their parents * children with a mental disorder in themselves or in their parents * children who had circumcision surgery (because the primary dressing was removed and crystallin spray was sprayed on the surgical area and the area was left open) * children who should not move before dressing (having hypospadias surgery) * children still in the intensive care unit at the time of the first surgical dressing * children whose dressing had to be changed before the second postoperative day (wetting, bleeding, opening, etc.) * children with previous play therapy experience

Keywords: anxiety fear hospitalized child dressings play operation
relaxation music to lower heart rate prior to cardiac ct

Conditions: Coronary Artery Disease and Cardiac Anatomy; Patients Undergoing Coronary CT Angiogram; Patients Undergoing CT Pulmonary Vein Angiogram; Patients Undergoing CT Calcium Score

Summary: to acquire low radiation dose and good quality cardiac ct images requires scanning at low heart rates which is usually done with beta-blockers. however, in some patients beta-blockers have little effect. this is thought to be due to a different mechanism of action which continues to maintain the heart rate despite administration of beta-blockers. this study aims to look at the effect of music or relaxation tracks to reduce patient heart rate as anxiety is thought to play a role in maintaining high heart rates. this study will randomise patients into a normal standard of care group compared to a normal standard of care group with music/ relaxation track and compare heart rate, radiation dose, image quality, amount of beta-blocker used and patient experience via a state-trait anxiety inventory (stai) questionnaire.


Eligibility criteria:
inclusion criteria: * age: 18 years and above * all patients coming in for non-contrast enhanced calcium score ct, pulmonary vein angiogram, or coronary ct angiogram exclusion criteria: * deaf * ct for transcatheter aortic valve implantation (tavi) or congenital heart disease patients * poor english literacy * pacemaker * post cabg * post heart transplant
a 12-weeks study to evaluate sulforaphane in the treatment of depression

Conditions: Depressive Disorder

Summary: major depressive disorder is a serious, recurrent and disabling mental disorder, which is the second leading cause of years lost to disability worldwide. accumulating evidence suggests the important role for inflammation and oxidative stress in the pathophysiology of depression. sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. previous studies suggested sulforaphane activates keap1-nrf2 system to prevent depression-like phenotype in mice. in this study, the investigator attempts to evaluate the efficacy, safety, and tolerability of sulforaphane plus a fixed oral antipressant in adult participants diagnosed with depression.

a total of 90 patients aged 18-55 years with depression will be included, all of whom gave informed consent. participants will receive 12 weeks of either sulforaphane or placebo per day, in addition to the existing treatment. baseline assessments include demographics, a comprehensive medical history, anthropometric measurements (weight and height), physical examination, and lab work. clinical symptoms will be assessed by the montgomery-a° sberg depression rating scale (madrs), hamilton depressive scale (hamd), hamilton anxiety scale(hama), and patient health questionnaire-9 (phq-9). the safety will be assessed by treatment emergent symptom scale (tess). the cognitive function will be evaluated by matrics consensus cognitive battery （mccb）at the beginning of the study and at week 12. the cranial mri is examined at baseline and repeated at week 12. the primary outcomes will be the effective time and the percentages of efficacy at 8 weeks, measured using the madrs. efficacy is defined as ≥50% decreases in the total score of madrs. secondary outcomes include global psychopathology, quality of life, functioning, cognition, biological data, safety and tolerability.

Eligibility criteria:
inclusion criteria: * 18-55 years old * clinical diagnosis of recurrent mdd or single-episode mdd with madrs≥22, cgi-si≥4 * be adherent to the continued oral antidepressant treatment medication exclusion criteria: * treatment-resistant depression * have known allergies, hypersensitivity, intolerance, or contraindications to ssri or any of the trial preparations * strong homicidal ideation/intent * pregnancy

Keywords: sulforaphane depression fatigue cognition
priming through timing. using opposing strategies to enhance motor learning for individuals with parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to determine how using auditory cues of a metronome at various frequencies impacts the gait mechanics and balance in people with parkinson's disease when walking over ground and on a treadmill. we will enroll 10 participants with a diagnosis of parkinson's disease (stages 2 or 3). all participants will complete 18 training sessions over 6 weeks and participate in pre- and post-testing of gait and balance.


Eligibility criteria:
inclusion criteria: * individuals with a diagnosis of parkinson's disease (made by movement disorders specialist) will be included in this study. additional inclusion criteria include: self-reported ability to walk \~6 minutes overground as well as walk on a treadmill for a total of 10 minutes with rest breaks as needed, and be classified as stage 2, or 3 on the hoehn and yahr scale (goetz et. al, 2004). exclusion criteria: * exclusion criteria include hoehn and yahr stages 1, 4, or 5, uncontrolled cardiorespiratory/metabolic disease (e.g., cardiac arrhythmia, uncontrolled hypertension or diabetes, orthostatic hypertension, chronic emphysema), or other neurological or orthopedic disorders that may affect walking. the investigators will also exclude participants with severe communication impairments, which could impede understanding of the purpose or procedures of the study or an inability to comply with experimental procedures.

Keywords: gait balance auditory cues
prognosis of hematological cancer patient underwent mechanical ventillation

Conditions: Hematological Malignancy; Acute Respiratory Failure; Mechanical Ventilation

Summary: this observational cohort aimed to re-evaluate the outcome of hematologic cancer patients admitted to the intensive care unit of mansoura oncology center through a cohort study as regards their need for mechanical ventilation during two years.

it has been believed for many years that the scene of cancer patients requiring mechanical ventilation is frustrating. the needed life support measures drain much of health resources and add a significant burden on the patient's family. many factors have been responsible for the high mortality rates among hematologic cancer patients admitted to intensive care unit. among of these factors, the invasive treatments that are frequently employed in today's intensive care unit. these procedures give chance for development of severe infection and multiple organ failure which are common events in immune-compromised patients (e.g. neutropenia) and in those exposed to chemotherapy. the most common form of organ failure in those patients is acute respiratory failure which is a major predictor of mortality in that population. the prognosis of such failure may vary depending on its causes and severity, co morbidity, associated acute organ failure and characters of the underlying malignancy. after the recent advances in the field of intensive care and shedding light on the benefits of the noninvasive ventilation in immune-compromised patients, the overall survival rate of cancer patients admitted to intensive care unit are improving.

Eligibility criteria:
inclusion criteria: * critical ill hematological cancer patient * requiring mechanical ventilation exclusion criteria: * patients with acute coronary syndrome. * patients with cancer remission more than 5 years.

Keywords: intensive care unit hematological malignancy acute respiratory failure prognosis mechanical ventilation
incidence and characterization of drivers oncogenes in the population with lung cancer afferents to the cancer institute in aviano (in.on.d.)

Conditions: Non Small Cell Lung Cancer

Summary: according to an analysis by memorial sloan kettering cancer center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it. in addition to that, therapies guided by analysis on mutations identified in ct-dna had a favorable impact, allowing longer survival. all this suggests that the presence of a therapeutically targetable oncogene (oncogene addicted) allows target therapy, resulting in a longer life expectancy. the main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with nsclc afferent to the cro. oncogene addiction is defined as being carriers of one of the mutations among egfr, alk, ret, kras, braf, her2, ros1, met or other mutations that become therapeutic targets under investigation.

according to an analysis by memorial sloan kettering cancer center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it. in addition to that, therapies guided by analysis on mutations identified in ct-dna had a favorable impact, allowing longer survival. all this suggests that the presence of a therapeutically targetable oncogene (oncogene addicted) allows target therapy, resulting in a longer life expectancy. the main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with nsclc afferent to the cro. oncogene addiction is defined as being carriers of one of the mutations among egfr, alk, ret, kras, braf, her2, ros1, met or other mutations that become therapeutic targets under investigation.

Eligibility criteria:
inclusion criteria: * first visit or first admission to cro occurred in the period from september 2023 to september 2028 * diagnosis of nsclc any stage exclusion criteria: - diagnosis of tumor not of certain lung origin (uncertain origin)
an extended feasibility phase i/ii study of methylenetetrahydrofolate (arfolitixorin) and pemetrexed single agent, given as neoadjuvant treatment in patients with resectable rectal cancer

Conditions: Rectal Cancer

Summary: the purpose of this study is to determine whether an optimal dose of \[6r\] 5,10-methylenetetrahydrofolate (arfolitixorin) in combination with pemetrexed are effective in pre-operative treatment of patients with resectable rectal cancer.


Eligibility criteria:
inclusion criteria: * pathological/ cytological diagnosis of adenocarcinoma of the rectum. patients must have operable rectal cancer that is amenable to surgery. * no prior therapy for rectal cancer * eastern cooperative oncology group (ecog) performance status 0 or 1 * adequate organ function * patient compliance and geographic proximity that allow adequate follow-up * for women: must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 3 months after treatment; must have a negative serum or urine pregnancy test and must not be lactating. * for men: must be surgically sterile or compliant with a contraceptive regimen during and for 3 months after treatment. * estimated life expectancy of at least 12 weeks * signed informed consent * at least 18 years of age exclusion criteria: * concurrent administration of any other anti-tumor therapy. * treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * serious concomitant systemic disorders (e.g., active infection including hiv, cardiac disease) that in the opinion of the investigator would compromise the patient's ability to complete the study. * have previously completed or withdrawn from this study or any other study investigating pemetrexed. * are pregnant or breast-feeding. * second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * history of significant neurological or mental disorder, including seizures or dementia. * inability to interrupt aspirin or other nonsteroidal anto-inflammatory drugs (nsaids) * presence of clinically relevant third-space fluid collection that cannot be controlled by drainage or other procedures prior to study entry. * inability or unwillingness to be given 5,10-methylenetetrahydrofolate, vitamin b12 or dexamethasone.

Keywords: 5,10-methylenetetrahydrofolate neoadjuvant therapy pemetrexed neoplasms rectal neoplasms colorectal neoplasms intestinal neoplasms gastrointestinal neoplasms digestive system neoplasms neoplasms by site rectal diseases digestive system diseases gastrointestinal diseases intestinal diseases pharmacologic actions therapeutic uses antineoplastic agents enzyme inhibitors molecular mechanisms of pharmacological action folic acid antagonists antimetabolites, antineoplastic antimetabolites
radiofrequency ablation of papillary thyroid microcarcinoma

Conditions: Papillary Thyroid Cancer

Summary: traditionally, surgery has been the standard recommendation for treating papillary thyroid cancer. the risk of surgery including permanent hoarseness, permanent hypocalcemia, a mid-cervical scar, and the potential for permanent hypothyroidism may be unacceptable for some patients, especially with low risk papillary thyroid carcinoma. the recent american thyroid association guidelines have proposed the option of active surveillance with low risk papillary thyroid cancer less than 210 mm. however, most patients find observation anxiety provoking knowing of having cancer. radiofrequency ablation (rfa) of small low risk papillary thyroid cancer is a promising therapeutic modality for these patients that reduces the risks associated with surgery and the anxiety of taking a watchful approach. however, this technique has not been validated in the north american population. the investigators aim to describe the investigators' initial experience with rfa of low risk papillary thyroid microcarcinoma (ptmc) compared to active surveillance (as) done by head and neck endocrine surgeons at johns hopkins medical institute. primary objective: * to evaluate the safety, efficacy and oncological outcomes of the procedure. secondary objective: * to determine the patient functional outcomes in comparison to the observational control.


Eligibility criteria:
inclusion criteria: * all patients regardless of sex or race between the ages 18-100 with biopsy proven ptmc with a bethesda v or vi pathology or indeterminate cytology on fine-needle aspiration cytology (fnac) who are recommended for treatment (bethesda iii/iv). * solitary thyroid nodule \<20mm in maximal dimension. * no sonographic evidence of extrathyroidal invasion, lymph node metastases, or distant metastases. * there must be at least 1 mm of normal tissue as a margin, without sonographic evidence of contact with the capsule. exclusion criteria: * patients with other histological types of thyroid malignancy other than papillary thyroid cancer such as medullary carcinoma, proto-oncogene serine/threonine kinase (braf) or telomerase reverse transcriptase (tert) mutations * clinically apparent multicentricity * lesions larger than 20 mm in maximum diameter. * recurrent laryngeal nerve palsy. * extension of nodule to posterior thyroid capsule. * ultrasound or other imaging studies revealing cervical lymph node involvement or distant metastases. * pregnancy. * pacemaker. * previous rfa.